Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ghadah S. Almuaythir"'
Autor:
Yazed S. Alruthia, Monira Alwhaibi, Mashal F. Alotaibi, Shatha A. Asiri, Bushra M. Alghamdi, Ghadah S. Almuaythir, Wejdan R. Alsharif, Hala H. Alrasheed, Yahya A. Alswayeh, Abdulaziz J. Alotaibi, Mohammad Almeshal, Saleh N. Aldekhail, Abdulrahman Alhusaini, Sulaiman A. Alrashed, Ali M. Alrumaih, Mohammed A. Dahhas, Mohammed A. Alghamdi, Mohammad S. Aleheidib, Mohamed H. Alhaidari, Jameel A. Alharbi, Aws Alshamsan
Publikováno v:
Saudi Pharmaceutical Journal, Vol 26, Iss 7, Pp 947-951 (2018)
Drug shortages are a multifaceted problem that has been recurring in Saudi Arabia over the past decade with its significant negative impact on patient care. However, there is a dearth of evidence about possible domestic reasons, if any, behind this r
Externí odkaz:
https://doaj.org/article/3d18431b6d16479a808837ce86aa7992
Autor:
Fahad A. Bashiri, Ghadah S. Almuaythir, Mohamad-Hani Temsah, Ibrahim Sales, Yazed AlRuthia, Hala H. Alrasheed, Wejdan R. Alsharif, Monira Alwhaibi, Fahad Alsohime
Publikováno v:
Patient preference and adherence
Yazed AlRuthia,1,2 Ghadah S Almuaythir,1 Hala H Alrasheed,1 Wejdan R Alsharif,1 Mohamad-Hani Temsah,3,4 Fahad Alsohime,3,4 Ibrahim Sales,1 Monira Alwhaibi,1 Fahad A Bashiri3,5 1Department of Clinical Pharmacy, College of Pharmacy, King Saud Universit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5f0a40510db6ac0ff2cabb2e56d9f4
https://doi.org/10.2147/ppa.s305849
https://doi.org/10.2147/ppa.s305849
Autor:
Rawan Alenazi, Shatha Asiri, Saja Almazrou, Wejdan R. Alsharif, Badr Aljohani, Ghadah S. Almuaythir, Yazed AlRuthia, Hala H. Alrasheed, Bushra M. Alghamdi, Maryam Alarfaj, Ahmed L. Alaofi, Omar Almazroo
Publikováno v:
Health Policy and Technology. 10:120-125
Background The recent incidents of generic drug recalls have shaken the public confidence in the quality of generic drugs in Saudi Arabia. Therefore, many clinicians and health policymakers are calling for the establishment of a national reference or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90953dba4a38dccaabbffec6e8c50acd
https://doi.org/10.1016/j.hlpt.2020.08.018
https://doi.org/10.1016/j.hlpt.2020.08.018
Autor:
Yazed AlRuthia, Maria Saeed, Othman Alharbi, Baraa HajkhderMullaissa, Abdulrahman M Aljebreen, Wejdan R. Alsharif, Ghadah S. Almuaythir, Nahla Azzam, Majid A Almadi, Hala H. Alrasheed
Publikováno v:
Journal of Medical Economics. 23:1102-1110
This study's objectives were to examine and compare the cost-effectiveness of biologic and non-biologic therapies in the improvement of the health-related quality of life (HRQoL) of patients with inflammatory bowel disease (IBD) in Saudi Arabia.This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b36c4438136fe10b7e0d2e9cca77e8
https://doi.org/10.1080/13696998.2020.1791889
https://doi.org/10.1080/13696998.2020.1791889
Autor:
Ghadah S. Almuaythir, Majid Abdularahman Almadi, Nahla Azzam, Hala H. Alrasheed, Maria Saeed, Othman Alharbi, Baraa HajkhderMullaissa, Abdulrahman M Aljebreen, Wejdan R. Alsharif, Yazed AlRuthia
Publikováno v:
Journal of Crohn's and Colitis. 14:S400-S401
Background The Ulcerative Colitis (UC) and Chron’s Disease (CD) are two debilitating Inflammatory Bowel Diseases (IBD) with an immense negative impact on patients’ health-related quality of life (HRQoL). Although several studies have examined the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0139923cad6984e9fe935dc95c49f09d
https://doi.org/10.1093/ecco-jcc/jjz203.573
https://doi.org/10.1093/ecco-jcc/jjz203.573
Autor:
Ghadah S. Almuaythir, Wejdan R. Alsharif, Sultan Alghadeer, Hala H. Alrasheed, Azher Arafah, Reem Alhaider, Fahad D. Alosaimi, Khalid Alsaleh, Yazed AlRuthia, Bushra M. Alghamdi, Shatha Asiri
Publikováno v:
Saudi Pharmaceutical Journal : SPJ
Saudi Pharmaceutical Journal, Vol 27, Iss 6, Pp 859-865 (2019)
Saudi Pharmaceutical Journal, Vol 27, Iss 6, Pp 859-865 (2019)
Background: Multiple scales in different languages were developed to measure patient-reported side effects of antineoplastics. However, these scales vary in their coverage of antineoplastics’ side effects, and none of them address both the severity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7310af901d3edfa84482f5cb744874
https://pubmed.ncbi.nlm.nih.gov/31516328
https://pubmed.ncbi.nlm.nih.gov/31516328